AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke.
The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon July 10 - 14, 2010.
On Wednesday, July 14, 2010, Dr. Joseph Schwarz, Chief Scientist of AlphaRx, will make an oral podium presentation of GAI-122 injectable nanoemulsion for neuroprotection. The results conclude that, based on the neuroprotective properties of GAI-122 and the increased concentration of GAI-122 in the brain after parenteral delivery relative to oral dosing, it is reasonable to expect that an injectable form of GAI-122 based on a nanoemulsion, will provide the required protection against damage to cognitive and behavioral functions in humans experiencing various ischemic disorders.
The Controlled Release Society (CRS) is an international organization consisting of 3,000 members from over fifty countries. Two-thirds of CRS membership are from the pharmaceutical industry and one-third consist of academic and government members. The CRS is the premier multidisciplinary society dedicated to the promotion of the science, technology, and innovative delivery of bio-actives for the benefit of humanity.